

Nature's npj Parkinson's Disease publishes clinical study with IRLAB's drug candidate IRL790

IRLAB announced today that a publication based on the clinical Phase Ib study with IRL790 in patients with Parkinson's disease and dyskinesias has been published in the reputed scientific journal *npj Parkinson's Disease* published by *Nature*.

IRL790 is one of IRLAB's leading drug candidates and is being developed for the treatment of dyskinesia and psychosis in Parkinson's disease. The clinical Phase Ib study shows that IRL790 is well tolerated and has a very good safety profile. Furthermore, the positive effect that dyskinesia decreased in the group treated with IRL790 was not shown in the placebo group. The drug candidate is now undergoing a clinical Phase IIa trial in a larger group of patients for further study of the effect observed in the Phase Ib study.

"Our study is now published in the journal *npj Parkinson's Disease*. This validates the research and is, of course, a major merit for IRLAB, our partners and the study's investigators," said Joakim Tedroff, Chief Medical Officer (CMO) at IRLAB.

npj Parkinson's Disease is an international journal, published by *Nature*, that highlights the most important scientific advances in Parkinson's disease research.

The publication: Svenningsson, P. *et al.* Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia—a phase 1b trial. *npj Parkinson's Disease*. DOI number 10.1038/s41531-018-0071-3.

Link to npj Parkinson's Disease: www.nature.com/npjparkd/

For further information

Nicholas Waters, CEO
Phone: +46 730 75 77 01
E-mail: nicholas.waters@irlab.se

Joakim Tedroff, CMO
Phone: +46 70 760 16 91
E-mail: joakim.tedroff@irlab.se

About IRLAB

IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson's disease.

IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson's disease. IRLAB also has additional programs in pre-clinical stages.

IRLAB's research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.

IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.

For more information, please visit www.irlab.se.